Roche’s faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing